Related Experiment Video
Updated: Jul 28, 2026
07:08
Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
Published on: September 5, 2017
Blood viscosity and oral anticoagulant therapy
American Journal of Clinical Pathology
|March 1, 1976
Summary
Bishydroxycoumarin reduced blood viscosity and hematocrit in healthy individuals and coronary heart disease patients. This viscosity reduction may explain the relief of anginal pain experienced by patients undergoing anticoagulant therapy.
Area of Science:
- Cardiovascular Medicine
- Hematology
Background:
- Coronary heart disease (CHD) is a leading cause of mortality worldwide.
- Blood viscosity is a critical factor in cardiovascular health and disease progression.
- Anticoagulant therapies are commonly used in managing cardiovascular conditions.
Purpose of the Study:
- To investigate the effect of bishydroxycoumarin on blood viscosity in healthy volunteers and patients with coronary heart disease.
- To explore the relationship between anticoagulant therapy intensity and blood viscosity.
- To determine if changes in blood viscosity correlate with clinical outcomes like anginal pain relief.
Main Methods:
- Blood samples were collected from nine healthy volunteers and 31 patients with coronary heart disease.
- Bishydroxycoumarin was administered, and changes in hematocrit, whole blood viscosity, and plasma viscosity were measured.
- The intensity of anticoagulant therapy was monitored, and its relationship with viscosity was analyzed.
- Drug discontinuation was observed to assess the reversibility of viscosity changes.
Main Results:
- Bishydroxycoumarin administration led to decreased hematocrit, whole blood viscosity, and plasma viscosity.
- The impact of anticoagulant therapy on viscosity varied individually.
- Viscosity levels returned to baseline within two to four days after discontinuing the drug.
- A potential correlation between decreased blood viscosity and relief of anginal pain was observed.
Conclusions:
- Bishydroxycoumarin effectively reduces blood viscosity and hematocrit.
- Individualized responses to anticoagulant therapy regarding blood viscosity are common.
- The observed decrease in blood viscosity may contribute to the therapeutic benefits of anticoagulants in coronary heart disease patients, particularly in alleviating anginal pain.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...